Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD
Intrahepatic cholangiocarcinoma (iCCA) is a fatal malignancy of the biliary system. The lack of a detailed understanding of oncogenic signaling or global gene expression alterations has impeded clinical iCCA diagnosis and therapy. The role of protein lactylation, a newly unraveled post-translational modification that orchestrates gene expression, remains largely elusive in the pathogenesis of iCCA. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 26, 2024 Category: Gastroenterology Authors: Long Yang, Kunwei Niu, Jianlin Wang, Weiwei Shen, Rui Jiang, Lu Liu, Wenjie Song, Xudan Wang, Xuan Zhang, Ruohan Zhang, Dan Wei, Ming Fan, Lintao Jia, Kaishan Tao Source Type: research
Trends in Current Use of Machine Perfusion for Donation after Cardiac Death Donors in the United States
The recent meta-analysis of machine-perfusion techniques for liver transplant by Parente et al.1 provides a much-awaited comprehensive assessment of the current literature on machine perfusion compared to static cold storage. With the promise of optimizing marginal and extended criteria grafts, and minimizing their risk of ischemic reperfusion injury, the transplant community has seen a progressive adoption of various perfusion strategies in the last several years. However, the landscape remains in flux regarding its optimal role and indications. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 26, 2024 Category: Gastroenterology Authors: Lauren E. Matevish, Parsia A. Vagefi, Madhukar S. Patel Tags: Letter to the Editor Source Type: research
Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe
We read with great interest the article by Lesley A. Patmore et al., published in the Journal of Hepatology, titled “Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe [1].” The study highlights that, among chronic hepatitis B (CHB) patients of Sub-Saharan African and Afro-Surinamese descent residing in Europe, the cumulative incidenc e rates of hepatocellular carcinoma (HCC) over 5 and 10 years are 1% and 2.4%, respectively. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 26, 2024 Category: Gastroenterology Authors: Mo-Yao Tan, Jun-Hua Su Tags: Letter to the Editor Source Type: research
Response to: The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease
We appreciate the interest that emerged from our recent publication [1], ‘Association between public health policies on alcohol and worldwide cancer, liver disease, and cardiovascular disease outcomes’ [2]. In our research, we evidenced a strong relationship between alcohol-related public health policies (PHP) establishment and the decrease of alcohol-related health consequences over time among 169 countries, including liver disease and other significant causes of burden of disease worldwide. These associations were stronger over time, and consistent with the framework SAFER proposed by the World Health Organization (W...
Source: Journal of Hepatology - April 26, 2024 Category: Gastroenterology Authors: Luis Antonio D íaz, Eduardo Fuentes-López, Juan Pablo Arab Tags: Letter to the Editor Source Type: research
Genomic testing for inborn errors of immunity in seronegative autoimmune hepatitis of childhood
Pandurangi et al. describe association of pathogenic variants in tumour necrosis factor alpha-induced protein 3 (TNFAIP3) which encodes the NF-kB regulatory protein A20, with seronegative and type II autoimmune hepatitis (AIH) of childhood.1 We would like to support their experience by reporting our own young paediatric patient harbouring a variant in TNFAIP3 who presented with indetermined acute liver failure (ALF), subsequently leading to progressive liver injury, histologically in keeping with seronegative AIH. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 26, 2024 Category: Gastroenterology Authors: Robert Hegarty, Nedim Hadzic Tags: Letter to the Editor Source Type: research
Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors
Lay summaryThis retrospective large serie of recent noncirrhotic portal vein thrombosis associated with local factors highlights that prothrombotic factors with high-risk of thrombosis identified in one-third of cases were highly associated with a risk of new thrombotic events. Recanalization and permanent anticoagulation prevented the risk of rethrombosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 25, 2024 Category: Gastroenterology Authors: Isabelle Ollivier-Hourmand, Louise Lebedel, Berta Bartroli Alabau, Odile Goria, Christophe Bureau, J érome Dumortier, Alexandra Heurgué, Christine Silvain, Victor De-Ledinghen, Pierre-Emmanuel Rautou, Audrey Payancé, Teresa García Ballester, Edilmar A Tags: Research Article Source Type: research
Every sheriff needs a deputy: targeting non-parenchymal cells to treat hepatic fibrosis
The landscape of anti-fibrotic drug development for liver disease is littered with failed clinical trials. In 2020, the CCR2 and CCR5 receptor antagonist, Cenicriviroc, failed to achieve its primary endpoint of fibrosis improvement of ≥1 stage without worsening of steatohepatitis at 12 months despite promising preclinical and phase 2 data[1]. This failure was particularly disappointing as it was one of the most promising immune-targeted therapeutics to reach phase 3 testing. In 2023, the FXR agonist, obeticholic acid, met the p rimary endpoint that Cenicriviroc could not, but the FDA voted against its approval for treatm...
Source: Journal of Hepatology - April 25, 2024 Category: Gastroenterology Authors: Brett McGettigan, Vijay Shah Tags: Editorial Source Type: research
Animal hepacivirus models for hepatitis C virus immune responses and pathology
Chronic HCV infection is a leading cause of cirrhosis and hepatocellular carcinoma. While curable with antiviral therapy, a vaccine is essential for HCV containment and eradication. Vaccine development ideally requires immunocompetent animal models, and in vitro systems for assessment of neutralising antibodies (nAbs). Engineered mouse models supporting HCV infection and replication are available but have blunted immune responses, limiting their suitability for vaccine studies. HCV incurred intrahepatic pathology also remains understudied due to the inaccessibility of human liver samples. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 24, 2024 Category: Gastroenterology Authors: Matthew J. Kennedy, Sonja Fernbach, Troels K.H. Scheel Tags: Hepatology Snapshot Source Type: research
Targeting EFHD2 Inhibits Interferon- γ Signaling and Ameliorates Non-Alcoholic Steatohepatitis
This study investigates the potential role of EF-hand domain family member D2 (EFHD2), a novel molecule specific to immune cells, in NASH pathogenesis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 24, 2024 Category: Gastroenterology Authors: Jiang-Tao Fu, Jian Liu, Wen-Bin Wu, Yi-Ting Chen, Guo-Dong Lu, Qi Cao, Hong-Bo Meng, Jie Tong, Jia-Hui Zhu, Xu-Jie Wang, Yi Liu, Chunlin Zhuang, Chunquan Sheng, Fu-Ming Shen, Xingguang Liu, Hua Wang, Yongsheng Yu, Yuefan Zhang, Hai-Yan Liang, Jia-Bao Zhan Tags: Research Article Source Type: research
Assessment of fatigue and its impact in chronic liver disease
Patient reported outcomes (PROs) such as health related quality of life (HRQL) are important outcome measures for patients with chronic liver diseases (CLDs). Presence of cirrhosis and advanced liver disease have been associated with worsened HRQL and fatigue. On the other hand, some patients with earlier stages of CLD such as primary biliary cholangitis (PBC), chronic hepatitis C viral infection (HCV) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), also experience fatigue causing PRO impairment. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 24, 2024 Category: Gastroenterology Authors: Zobair M. Younossi, Andreas E. Kremer, Mark G. Swain, David Jones, Christopher Bowlus, Michael Trauner, Linda Henry, Lynn Gerber Tags: Research Article Source Type: research
Reply to: “Democratising the scientific method”
Don't let a letter divide us (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 22, 2024 Category: Gastroenterology Authors: Paolo Angeli Tags: Letter to the Editor Source Type: research
A different picture on liver biopsy
A 32-year-old was referred to her local gastroenterologist for investigation of longstanding abnormal liver biochemistry. Her past medical history was of hepatic steatosis, pulmonary sarcoidosis and suspected ileal sarcoidosis. Sarcoidosis was in longstanding clinical remission. There was no relevant family history. She reported fatigue and myalgia. Her body mass index was 22, and physical examination was unremarkable. Labs showed a mildly elevated bilirubin, 35 μmol/L (normal range [NR] 3-20), mildly elevated ALT 51 U/L (NR 10-35) and total protein of 84 U/L (NR 60-80). (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 17, 2024 Category: Gastroenterology Authors: Ashley Barnabas, Rosa Miquel Tags: What Is Your Diagnosis? Source Type: research
From the Editor ’s Desk...
Metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). However, given that MASLD requires at least one cardiometabolic risk factor, questions were raised as to whether new evidence would need to be generated for MASLD. In this issue, Younossi and coworkers compared the clinical profile and outcomes of NAFLD to MASLD using a tertiary-care NAFLD database and NHANES-III. Ninety-nine percent of included patients met MASLD criteria while 95% met MASLD criteria on BMI only. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 17, 2024 Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research
JHEP at a glance (May 2024)
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 17, 2024 Category: Gastroenterology Source Type: research
Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 17, 2024 Category: Gastroenterology Source Type: research
